- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Health Bulletin 9/December/2021 - Video
Overview
Here are Top Health stories of the day
NEET PG Counselling Delay: Health Ministry Urges SC for Speedy Hearing, Doctors warn of protest escalation
Although there is no solution to the pending NEET PG Counselling process and the continuous protest by the resident doctors across the country, the Union Health Ministry has recently urged the Supreme Court for early listing and hearing of the matter on the EWS reservation matter.
This comes after the Health Minister himself had promised the resident doctors at RML Hospital that the Central Government would press for an early hearing of the matter.
For more details, check out the full story on the link below:
IMA warns of 'massive third wave' amid Omicron threat, urges public to follow COVID-19 protocols
The Indian Medical Association (IMA) urged the government to announce "additional" doses of Covid vaccine for healthcare, frontline workers, and immunocompromised individuals amid concerns over Omicron, 21 cases of which have been detected in India so far.
It also demanded that the government expedite the proposal of vaccinating individuals aged 12 to 18 years.
For more details, check out the full story on the link below:
3rd Wave Will Be There, Will Be Massive: IMA
13 lakh Plus Registered Allopathic doctors, 596 Medical Colleges in India: Health Minister
As of November 2021, the number of registered medical practitioners in India is more than 13 lakhs, informed Dr. Bharati Pravin Pawar, the MoS Health.
The Minister of Health has further informed the upper house of the Parliament that the doctor-patient ratio in India is 1:834, better than WHO recommendation, assuming 80% availability of registered allopathic doctors and 5.65 lakh AYUSH practitioners.
For more details, check out the full story on the link below:
13 Lakh Plus Registered Allopathic Doctors, 596 Medical Colleges In India: Health Minister
AIIMS INI CET January 2022 session: 41 MD, MS seats up available for PwBD candidates
Through a recent notice, the All India Institute of Medical Sciences (AIIMS), has released the Final Seat Position for candidates seeking PG medical admissions via INI-CET January 2022 session in Persons with Benchmark Disabilities (PwBD) category this academic year.
According to the seat position, a total of 41 MD, MS seats are available for disabled candidates this year across AIIMS.
For more details, check out the full story on the link below:
AIIMS INI CET January 2022 Session: 41 MD, MS Seats Up Available For PwBD Candidates
Alembic Pharma gets USFDA nod for pulmonary arterial hypertension drug Selexipag
Drugmaker, Alembic Pharmaceuticals Limited, announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg.
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Uptravi Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg, of Actelion Pharmaceuticals, Ltd. (Actelion).
For more details, check out the full story on the link below:
Alembic Pharma Gets USFDA Nod For Pulmonary Arterial Hypertension Drug Selexipag